The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...

The approval was supported by the randomized, double-blind, placebo-controlled phase 3 ADRIATIC study. Results showed durvalumab reduced the risk of death by 27% and disease progression or death ...

The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and ...

rare type of small cell lung cancer that primarily affects younger people who have never ... Aug. 23, 2024 — A team of researchers has created a digital pathology platform based on artificial ...

New, Rare Type of Small Cell Lung Cancer Identified Sep. 11 ... Aug. 23, 2024 — A team of researchers has created a digital pathology platform based on artificial intelligence.

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...

Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The non-small cell lung cancer (NSCLC) drug osimertinib (Tagrisso) was associated ...

Most non-small-cell lungcancer is caused by smoking, but your genes may also help determine your chances of getting the disease. Lung cancer is when cell growth in the lungs becomes abnormal and ...